Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Jiwoong LimDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-8603-9816
Lilly F ChiouDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Brandon NovyCenter for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Emma J ChowCenter for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jacqueline L Norris-DrouinDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
P Brian HardyDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Konstantin I PopovDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Albert A BowersDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8214-7484
Kenneth H PearceDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8138-5421
Funding
NRSA in GeneticsT32GM135128 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Daniel J McKay, JEFF J. SEKELSKY · 2020 to 2026
$5.1M
MIRA Equipment SupplementR35GM125005 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Albert A Bowers · 2017 to 2026
$3.9M
Pathological Reprogramming of DNA Damage Signaling in Neoplastic CellsR01ES029079 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.3M
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic targetR01CA229530 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.0M
Molecular and Cellular Biophysics Training GrantT32GM148376 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Matthew R Redinbo, Qi Zhang · 2024 to 2026
Melanoma-associated antigen A4 (MAGE-A4) is a cancer/testis antigen (CTA) that interacts with the E3 ubiquitin ligase RAD18 to enhance DNA damage tolerance in tumor cells. Here, we report the structure-guided optimization of a previously reported potent but cell-impermeable cyclic peptide, called
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development of Next Generation Cell-Permeable Peptide Inhibitors for the Oncological Target MAGE-A4. · full record | OpenQuestion